Context: Soluble CD163 (sCD163) was suggested as a biomarker of insulin sensitivity and CD163 mRNA expression representing macrophage content in adipose tissue (AT).
O besity is associated with systemic and adipose tissue low-grade inflammation that has been postulated to be involved in the development of insulin resistance, type 2 diabetes mellitus (T2DM) and other obesity-related comorbidities (1) . This low-grade inflammation is characterized by an increased recruitment of monocytes/macrophages in adipose tissue (AT) (2) . Macrophages in AT produce and secrete proinflammatory cytokines, eg, TNF␣ or IL-6. TNF␣ is expressed as a membrane-bound protein (3) and is cleaved into a soluble form by TNF-␣-converting enzyme (TACE) also called as a disintegrin and metalloproteinase domain 17 (ADAM 17) (3) . Recently it was shown that TACE/ADAM 17 acts also as a shedding enzyme for haptoglobin-hemoglobin complex receptor CD163 (4, 5) . This glycosylated protein expressed predominantly by tissue macrophages may be released from cellular surface as soluble CD163 (sCD163). Thus, circulating sCD163 could be produced by AT macrophages similarly as soluble TNF␣. sCD163 levels in circulation were found to be increased in obese and T2DM patients (6 -8) , and its serum levels correlated with body fat mass (6) . Moreover, sCD163 was found to be a strong predictor of a risk of the development of T2DM (8, 9) . Circulating levels of sCD163 were recently proposed as a biomarker of the whole-body insulin resistance and other indices of metabolic syndrome (MS) (8, 10) . Moreover, based on the cellular origin of CD163, Parkner et al (10) hypothesized that circulating sCD163 levels are linked to CD163 expression and macrophage content in AT. However, up until today, no studies investigating this relationship are available.
Therefore, the first aim of this study was to investigate the relationship between serum sCD163 levels and CD163 mRNA levels in both cross-sectional and prospective design. Circulating sCD163 and CD163 mRNA expression in sc and visceral (visc) adipose tissue were determined in a cohort of women with a wide range of body mass index (BMI) and in a cohort of obese women submitted to longterm dietary intervention. In addition, to further examine the production of soluble form of CD163, mRNA expression of enzymes involved in the regulation of CD163 shedding [TACE and tissue inhibitor of metalloproteinase 3 (TIMP3)] was explored during dietary intervention. The second aim of the study was to investigate, in both cohorts, the association between circulating sCD163 and insulin sensitivity when measured by euglycemic-hyperinsulinemic clamp.
Materials and Methods

Subjects
Two cohorts of subjects participated in the study.
Cohort 1
Forty-two women with a wide range of BMI (aged 21-66 y,  BMI 17-49 kg/m 2 ) scheduled to have abdominal surgery (laparoscopic cholecystectomy, hysterectomy, or gastric banding) were included in the study. Exclusion criteria were malignancy, inflammatory conditions, congestive heart failure, chronic liver or kidney disease, psychiatric disorders, and body weight fluctuations greater than 3 kg over the preceding 3 months. According to the BMI, the presence or absence of the MS [evaluated according to the International Diabetes Federation criteria (11) ], 42 participants were stratified into three groups [lean (n ϭ 10 subjects), obese (n ϭ 18), and obese with MS (n ϭ 14)].
Cohort 2
This cohort consisted of 27 obese premenopausal women (aged 38 Ϯ 1 y; BMI 38 Ϯ 2 kg/m 2 ). Exclusion criteria were malignancy, inflammatory conditions, hypertension, diabetes, hyperlipidemia treated by drugs, weight change of greater than 3 kg within the 3 months prior to the study, drug-treated obesity, pregnancy, participation in other trials, and alcohol or drug abuse. Written informed consent was obtained from all subjects. This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Ethical Committee of the Third Faculty of Medicine of Charles University in Prague, Czech Republic.
Study design
Study 1 (cohort 1)
Clinical investigation was realized 7-14 days prior to the surgery. Anthropometric measurements, blood sampling, and euglycemic-hyperinsulinemic clamp were performed at rest after an overnight fast. Body composition was evaluated using bioelectrical impedance (QuadScan 4000; Bodystat). Visc and sc fat areas were assessed using computed tomography scans at the level L4 -5 (12) . The two-dimensional area calculation was used; three slides were taken into consideration. Blood samples were obtained before the clamp and plasma parameters were measured using standard procedures. Insulin sensitivity was assessed using euglycemic hyperinsulinemic clamp according to De Fronzo et al (13) . During the surgical procedure, paired samples of sc abdominal and omental visc adipose tissue were obtained and processed immediately. AT was washed in physiological saline, homogenized in RLT lysis buffer (QIAGEN) and stored at Ϫ80°C until total RNA extraction.
Study 2 (cohort 2)
Participants underwent dietary intervention consisting of a 1-month very low-calorie-diet (VLCD) (800 kcal/d, liquid formula Redita; Promil) and a subsequent weight-stabilization phase. The latter consisted in a 2-month low-calorie diet (600 kcal/d less than the estimated energy requirement) followed by a 3-month weight-maintenance phase. Patients consulted a dietitian once a week during energy restriction (VLCD and low calorie diet) and once a month during the weight-maintenance phase. They provided a written 3-day dietary record at each dietary consultation during the weight stabilization.
Clinical investigation, anthropometric measurements, and blood sampling were performed in the morning at a fasting state at baseline (before the dietary intervention) and at the end of VLCD and weight-stabilization phases. Needle biopsy of sc abdominal AT was performed under local anesthesia (1% xylocaine; AstraZeneca PLC) from the abdominal region (14 -20 cm lateral to the umbilicus) (14) . In 23 women, the euglycemichyperinsulinemic clamp was performed according to the method of De Fronzo et al (13) . The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as fasting blood glucose (millimoles) ϫ fasting insulin (milliunits per liter)/22.5.
Blood analysis
Plasma levels of glucose, insulin, lipids, and C-reactive protein were determined using standard methods. Serum concentration of sCD163 was determined by a human CD163 quantikine ELISA kit (R&D Systems). The interassay precision of the current assay was 2.63% Ϯ 0.9%, and the limit of detection was 1.55 ng/mL. The TNF␣ concentration in plasma was analyzed using a high-sensitivity human cytokine Lincoplex kit (Merck-Millipore).
Quantitative RT-PCR
Total RNA isolation was performed as previously described (14) . Genomic DNA was removed by deoxyribonuclease I treatment (Invitrogen). cDNA was obtained by reverse transcription (high capacity cDNA reverse transcription kit; Applied Biosystems). The mRNA expression of CD163, CD68, TNF␣, TACE/ ADAM17, and TIMP3 was assessed by real-time quantitative PCR on ABI PRISM 7900 or 7500 sequence detection system using custom TaqMan low-density arrays or a TaqMan gene expression assay (Applied Biosystems). The level of expression of the target genes was normalized to glucuronidase beta or peptidylprolyl isomerase A, and fold change of expression was calculated using the ⌬⌬-cycle threshold (Ct) method.
Statistical analysis
Study 1
To compare plasma and mRNA levels between the three groups of individuals, log-transformed data were analyzed by one-way ANOVA with Bonferroni post hoc analysis using GraphPad Prism version 6.00 for Windows (GraphPad Software). Correlations between the respective variables were assessed using the Pearson's parametric test.
Study 2
To evaluate the diet-induced evolution of clinical variables and plasma and mRNA levels, data were log transformed and analyzed using ANOVA with repeated measures. Correlations between the diet-induced relative changes of respective variables were assessed using the Pearson's parametric test (GraphPad Software). Data were expressed as means Ϯ SEM. P Ͻ .05 was considered statistically significant.
Results
Study 1: cross-sectional
Clinical and metabolic characteristics of the three groups of subjects (lean, obese, and obese with MS) are shown in Table 1 . The glucose disposal rate related to body weight or fat-free mass was lower in both obese and obese with MS, when compared with the lean.
Serum levels of sCD163 were higher in both obese and obese with MS than in the lean group ( Figure 1A) . The plasma levels of TNF␣ were not different between the Abbreviations: CT, computed tomography; GDR FFM , glucose disposal rate related to fat-free mass; GDR kg , glucose disposal rate related to body weight; HDL, high-density lipoprotein; MS, metabolic syndrome; NEFA, nonesterified free fatty acid. a P Ͻ .05 compared with lean.
groups. CD163, CD68, and TNF␣ mRNA levels were higher in obese and obese with MS subjects than in lean in both fat depots ( Figure 1B ).
Correlations
Circulating sCD163 levels correlated positively with CD163 mRNA and also with CD68 mRNA expression in both visc and sc AT ( Table 2 and Supplemental Figure 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org). CD68 mRNA correlated with CD163 mRNA levels in both fat depots (Table  2) . Interestingly, when adjusted to BMI, the correlation between sCD163 levels and mRNA expression in sc AT remained significant (r ϭ 0.44; P ϭ .004), whereas the correlation between sCD163 and mRNA expression in visc AT disappeared (r ϭ 0.23; P ϭ .8). Positive correlations were found between both sCD163 and CD163 mRNA expression in AT, and with most of the variables related to the amount of body fat mass, but not with the amount of visc AT (Table 2) .
Importantly, inverse correlations were found between both sCD163 and CD163 mRNA levels in AT, and glucose disposal rate related either to the body weight or fat-free mass (Table 2 and Supplemental Figure 1 ).
Study 2: dietary intervention
Clinical and metabolic characteristics of subjects in cohort 2 before and during dietary intervention are summa- Figure 1 . Study 1 (cross-sectional study): plasma/serum (A) and mRNA (B) levels of CD163, CD68, and TNF␣ of lean (LE; n ϭ 10), obese (OB; n ϭ 18), and obese patients with MS (OB/MS; n ϭ 14). mRNA expression in sc (SAT) and visc (VAT) AT was normalized to GUSB, and fold change of expression was calculated using the ⌬⌬Ct method. Values are means Ϯ SEM. **, P Ͻ .01 compared with lean; ***, P Ͻ .001 compared with lean; $, P Ͻ .05 compared with SAT. rized in Table 3 . The body weight was decreased by 11.3% at the end of dietary intervention. The whole-body insulin sensitivity improved as measured by HOMA-IR or glucose disposal rate. The AT sensitivity to antilipolytic effect of insulin (measured as a decrease of plasma free fatty acids levels during hyperinsulinemic clamp) was not changed during the diet (data not shown). Dietary intervention induced a decrease of sCD163 serum concentration at the end of the VLCD and weight stabilization when compared with the baseline values (Figure 2A) . Plasma levels of TNF␣ were higher than baseline at the end of VLCD and decreased to the baseline levels at the end of weight stabilization (Figure 2A) . mRNA levels of CD163 and CD68 were higher at the end of VLCD when compared with the baseline and both of them decreased to the levels not different from baseline at the end of weight stabilization ( Figure 2B ). TNF␣ and TACE mRNA expression did not change significantly throughout the entire dietary intervention, whereas that of TIMP3 increased above the baseline at the end of weight stabilization ( Figure 2B ).
Correlations
At baseline, serum sCD163 correlated positively with CD163 and CD68 mRNA in sc AT (r ϭ 0.579, P Ͻ .001; r ϭ 0.383, P Ͻ .05), similarly to Study 1. However, the diet-induced change of circulating sCD163 did not correlate with the CD163 or CD68 mRNA levels either during VLCD or during the entire dietary intervention ( Table 4) . The diet-induced changes of CD163 mRNA expression correlated with the mRNA changes of CD68, TNF␣, TIMP3, or TACE (Table 4) .
In addition, despite the fact that baseline values of sCD163 and CD163 mRNA correlated inversely with glucose disposal rate (r ϭ Ϫ0.625, P Ͻ .01; r ϭ Ϫ0.845, P Ͻ .01, respectively), the diet-induced changes of sCD163 and CD163 mRNA during the VLCD or during the entire dietary intervention did not correlate with the changes of insulin sensitivity (Table 4) . The diet-induced changes of CD163 mRNA levels also did not correlate with the changes of body weight, BMI, or fat mass (data not shown).
Discussion
The aim of this study was to elucidate whether the concentration of sCD163 in blood reflects the CD163 mRNA expression in adipose tissue and whether sCD163 plasma concentrations and AT mRNA levels are associated with insulin sensitivity. In a cohort of women with a wide range of BMI and insulin sensitivity, we found a positive correlation between mRNA expressions of CD163 in both sc and visc AT, in respect to circulating sCD163 levels. Thus, we bring an evidence for a previous suggestion of a link between circulating sCD163 and CD163 expression in sc AT (10, 15) , and, in addition, we find the same link with respect to CD163 expression in visc AT. Moreover, the correlation of sCD163 levels with mRNA expression of macrophage marker CD68 suggests that serum sCD163 might be perceived as a possible indicator of macrophage activation in AT. Interestingly, the correlation of sCD163 with CD163 mRNA expression in visc AT disappeared after adjustment to BMI, whereas the correlation with expression in sc AT remained significant. This finding may suggest that sc AT is a more important contributor to sCD163 when compared with visc fat.
Next, we documented a strong relationship between insulin sensitivity, measured by the gold standard method of euglycemic hyperinsulinemic clamp, and circulating sCD163. These results extend the previously reported findings of a close relationship between sCD163 and HOMA-IR (8, 10) . In this study, insulin sensitivity correlated also with CD163 mRNA expression in both fat depots. Thus, we demonstrate the capacity of sCD163 as a biomarker of insulin sensitivity measured by the clamp method at steady-state condition.
However, in a dynamic condition represented by the weight-reducing hypocaloric diet, the above-mentioned associations were not present: the diet-induced change of sCD163 showed different pattern and did not correlate with the change of CD163 mRNA levels in sc AT either during the initial dynamic phase of the dietary intervention (VLCD) or during the phase of the weight stabilization. Indeed, although the sCD163 serum levels were lower than baseline at the end of both phases of the diet, the mRNA levels increased during VLCD and then decreased to the baseline at the end of the weight stabilization. The same pattern of evolution was found for the other macrophage marker CD68. This time course is in agreement with our previous results showing the diet-induced responses of macrophage markers in adipose tissue during multiphase dietary intervention (14, 16, 17) . It is to be noted that CD163 is considered as M2 macrophage marker, similarly as lymphatic vessel endothelial receptor 1, which expression during dietary intervention exhibited the same pattern (data not shown). The increased expression of these markers after strong caloric restriction could be associated with active remodeling of AT during this intervention (18) . However, in humans, the phenotypic diversity of AT macrophages is now known to include more than two types of macrophage states (19) .
The discrepancy between the dynamics of CD163 in circulation and in AT could be caused by diet-induced adaptations at the translational or posttranslational level of the specific protein. Among factors influencing sCD163 production could be the efficiency of shedding of the CD163 molecule from the macrophage surface. Both CD163 and TNF␣ are shed from the cellular surface by TACE that is inhibited by the metalloproteinase inhibitor TIMP3 (20) . However, no relevant change of TACE mRNA expression in AT throughout the dietary intervention was found, and the TIMP3 mRNA level slightly increased at the end of weight stabilization, ie, later than the decrease of sCD163 levels occurred. Therefore, the changes in the shedding of CD163 in AT during dietary intervention probably do not contribute to the changes of sCD163 in circulation.
The difference between the serum and expression of CD163 by AT macrophages during diet might be therefore related to contributions of other tissues to circulating sCD163. CD163 is expressed in macrophages resident in many nonadipose tissues, eg, liver, muscle, kidney (21) (22) (23) (24) , and also in blood monocytes (25) . Unfortunately, to our knowledge, there are no studies that evaluate direct contribution of other tissues to circulating levels of sCD163 or investigating CD163 expression in other tissues or cells during dietary intervention. In this study the evolution of sCD163 paralleled that of the glucose disposal rate when measured using a hyperinsulinemic clamp during weight-reducing dietary intervention. However, the direct correlations between the diet-induced changes of sCD163 and those of glucose disposal rate were not found. Similarly, no correlation was found between the diet-induced changes of CD163 mRNA expression and insulin sensitivity. Consequently, we conclude that, in a dynamic condition of a weight-reducing hypocaloric diet, the change of sCD163 in circulation and CD163 mRNA expression in sc AT is not a quantitative biomarker of the change of the whole-body insulin sensitivity. These findings suggest that circulating levels of sCD163 and AT mRNA expression of CD163 are probably not in a cause-effect relationship with insulin sensitivity. But we believe that it does not invalidate the assumption that sCD163 could be used as a biomarker of insulin resistance under steady-state conditions.
As mentioned above, the variations in CD163 mRNA expression in AT measured in this study reflect the macrophage content in adipose tissue as well as the very expression of CD163 in each of the macrophages resident in AT. Thus, no direct conclusions about the relationship between sCD163 and macrophage content in AT may be made based on this study. However, it is to be noted that the pattern of evolution of CD163 mRNA expression in AT in this study was similar to the pattern of macrophage marker CD68 and to other macrophage markers observed during the same multiphase dietary intervention in our recent study (14) .
In conclusion, in this study we demonstrated a quantitative association between the circulating levels of sCD163 and mRNA expression of macrophage markers CD163 and CD68 in sc and visc adipose tissue in the steady-state condition. Furthermore, in the steady-state condition, we found a negative correlation between sCD163 levels and insulin sensitivity as assessed using a hyperinsulinemic euglycemic clamp. However, in a dynamic condition represented by a weight-reducing hypocaloric diet, there is no such relationship between the diet-induced changes of the above-mentioned variables. Thus, there is no evidence that sCD163 might be used as a quantitative biomarker of the diet-induced changes of AT CD163 expression or changes of insulin sensitivity. Therefore, further research of the translational or posttranslational processes involved in sCD163 production during diet and other physiological stimuli is warranted.
